Abstract
Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis. Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clinical trials. This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.
Similar content being viewed by others
References
Astellas Pharma. Oral JAK inhibitor Smyraf® tablets approved in Japan for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have an inadequate response to conventional therapies [media release]. 26 Mar 2019. https://www.astellas.com/en/news/14651.
Astellas Pharma. Smyraf® tablets 50 mg and 100 mg: prescribing information. 2019. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/800126_39990C6F1020_1_03. Accessed 1 Apr 2019.
Janssen Biotech. Janssen announces worldwide agreement to develop and commercialize JAK inhibitor for immunological diseases [media release]. 1 Oct 2012. http://www.janssenbiotech.com.
Astellas Pharma. Astellas announces end of license agreement with Janssen to develop and commercialize ASP015K [media release]. 2 Dec 2014. http://www.astellas.com.
Ito M, Yamazaki S, Yamagami K, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017;133(1):25–33.
Higashi Y, Inami M, Ito M, et al. ASP015K: a novel JAK inhibitor demonstrated potent efficacy in a chronic oxazolone-induced dermatitis model in rats [abstract no. P093]. Dermatol Ther. 2012;2(Suppl):S41–2.
Cao YJ, Sawamoto T, Valluri U, et al. Pharmacokinetics, pharmacodynamics, and safety of ASP015K (peficitinib), a new janus kinase inhibitor, in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(6):435–49.
Zhu T, Howieson C, Wojtkowski T, et al. The effect of verapamil, a p-glycoprotein inhibitor, on the pharmacokinetics of peficitinib, an orally administered, once-daily JAK inhibitor. Clin Pharmacol Drug Dev. 2017;6(6):548–55.
Zhu T, Oda K, Valluri U, et al. Coadministration of ASP015K, a novel janus kinase inhibitor, with methotrexate demonstrates tolerability and lack of pharmacokinetic interactions in patients with rheumatoid arthritis [abstract no. AB0363]. Ann Rheum Dis. 2013;72(Suppl. 3):898.
Zhu T, Parker B, Wojtkowski T, et al. Drug interactions between peficitinib, an orally administered, once-daily janus kinase inhibitor, and rosuvastatin in healthy subjects. Clin Pharmacokinet. 2017;56(7):747–57.
Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to Dmards [abstract no. 887]. Arthritis Rheumatol. 2018;70(Suppl. 9):983–4.
Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to methotrexate [abstract no. 888]. Arthritis Rheumatol. 2018;70(Suppl. 9):985–6.
Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75(6):1057–64.
Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):932–42.
Kivitz AJ, Gutierrez-Urena SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–19.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd/Springer Nature, and Susan Keam, a salaried employee of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Markham, A., Keam, S.J. Peficitinib: First Global Approval. Drugs 79, 887–891 (2019). https://doi.org/10.1007/s40265-019-01131-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-019-01131-y